Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)
Document Type
Journal Article
Publication Date
1-2021
Journal
EClinicalMedicine
Volume
31
DOI
10.1016/j.eclinm.2020.100693
APA Citation
Bennett, C. L., Hoque, S., Olivieri, N., Taylor, M. A., Aboulafia, D., Lubaczewski, C., Bennett, A. C., Vemula, J., Schooley, B., Witherspoon, B. J., Godwin, A. C., Ray, P. S., Yarnold, P. R., Ausdenmoore, H. C., Fisherman, M., Herring, G., Ventrone, A., Aldaco, J., Hrushesky, W. J., Restaino, J., Thomsen, H. S., Marx, R., Migliorati, C., Ruggiero, S., Nabhan, C., Carson, K. R., McKoy, J. M., Yang, Y. T., Schoen, M. W., Knopf, K., Martin, L., Sartor, O., Rosen, S., & Smith, W. K. (2021). Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine, 31 (). http://dx.doi.org/10.1016/j.eclinm.2020.100693
Peer Reviewed
1
Open Access
1
